1.Huang X# , Yan J#, Zhang M# , Wang Y#, Chen Y, Fu X, Wei R, Zheng X，Liu Zh, Zhang X; Yang H，Hao B, Shen Y, Su Y, Cong X, Huang M, Tan M*, Ding J*, Geng M*.Targeting Epigenetic Crosstalk as a Therapeutic Strategy for EZH2-aberrant Solid Tumors, Cell, 2018;175(1):186-199. （IF：31.398）
2.Zeng H#, Qu J#, Jin N#, Xu J, Lin C, Yang X, He X, Tang S, Lan X, Yang X, Chen Z, Huang M*, Ding J*, Geng M*.Feedback activation of leukemia inhibitory factor receptor limits response to histone deacetylases inhibitors in breast cancer. Cancer Cell, 2016;30(3):459-73. （IF：22.844）
3.Lian Q, Xu J, Yan S, Huang M*, Ding H, Sun X, Ding J*, Sun B* and Geng M*. Chemotherapy-induced intestinal inflammatory responses are mediated by exosome secretion of double-strand DNA via AIM2 inflammasome activation. Cell Res 2017;27(6):784-800. （IF：15.393）
4.Wang X#, Zhang M, Ping F, Liu H, Sun J, Wang Y, Shen A, Ding J*, Geng M*. Identification and therapeutic intervention of coactivated anaplastic lymphoma kinase, fibroblast growth factor receptor 2, and ephrin type‐A receptor 5 kinases in hepatocellular carcinoma. Hepatology. 2019;69(2):573-586（IF：14.079）
5.Yue X, Ai J, Xu Y, Chen Y, Huang M, Yang X, Hu B, Zhang H, He Ch, Yang X, Tang W, Peng X, Dong L, Wang H, Fan J*, Ding J*, Geng M*. Polymeric immunoglobulin receptor promotes tumor growth in hepatocellular carcinoma. Hepatology. 2017;65(6):1948-1962. （IF：14.079）
6.Chen Y, Wang Y, Zhang J, Su Y, Shen Y, Jiang D, Hou Y , Geng M*, and Ding J*. G9a regulates breast cancer growth by modulating iron homeostasis through the repression of ferroxidase hephaestin . Nature Commun. 2017 8(1):27. （IF：12.353）
7.Dai X, Yan J, Fu X, Pan Q, Sun D, Xu Y, Wang J, Nie L, Tong L, Shen A, Zheng M, Huang M, Tan M, Liu H, Huang X*, Ding J*, Geng M*. Aspirin inhibits cancer metastasis and angiogenesis via targeting heparanase. Clin Cancer Res. 2017;23(20):6267-6278. （IF：10.199）
8.Liu H, Ai J, Shen A, Chen Y, Wang X, Peng X, Chen H, Shen Y, Huang M*, Ding J*, Geng M*.c-Myc alteration determines the therapeutic response to FGFR inhibitors. Clin Cancer Res. 2017; 23(4):974-984. （IF：10.199）
9.Sun W#, Xie Z#, Liu Y#, Zhao D#, Wu Z, Zhang D, Lv H, Tang S, Jin N, Jiang H, Tan M, Ding J, Luo C*, Li J*, Huang M*, Geng M*. JX06 selectively inhibits pyruvate dehydrogenase kinase PDK1 by a covalent cysteine modification. Cancer Res, 2015 ,75(22):4923-36. （IF：9.13）
10.Shen A#, Wang L#, Huang M, Sun J, Chen Y, Shen Y, Yang X, Wang X, Ding J*, Geng M*. c-Myc alterations confer therapeutic response and acquired resistance to c-Met inhibitors in MET-addicted cancers. Cancer Res, 2015 ,75(21):4548-59. （IF：9.13）
